Provided by Tiger Trade Technology Pte. Ltd.

SpyGlass Pharma, Inc.

28.04
+0.72502.65%
Volume:99.27K
Turnover:2.76M
Market Cap:934.05M
PE:-16.73
High:28.13
Open:27.68
Low:27.29
Close:27.31
52wk High:32.44
52wk Low:17.06
Shares:33.32M
Float Shares:10.78M
Volume Ratio:1.49
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6760
EPS(LYR):-17.9825
ROE:-67.71%
ROA:-37.23%
PB:4.02
PE(LYR):-1.56

Loading ...

Stockland Director Adjusts Stapled Security Holdings Amid Tax-Related Sales

TIPRANKS
·
Yesterday

Stockland Director Penelope Winn Lifts Indirect Stake via On-Market Buy

TIPRANKS
·
Sep 09

Stockland Director Increases Holding in Stapled Securities

TIPRANKS
·
Sep 04

SpyGlass Pharma Management to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 02

SpyGlass Pharma to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Solana (SOL) Governance Voting Goes Wild: Kraken Changes Vote to Save $1.5 Billion Inflation Plan

utoday
·
Aug 28

Stockland Director Kathryn McKenzie Increases Indirect Stapled Security Holding

TIPRANKS
·
Aug 27

BTC Digital signs three-party MOU to advance AI data center project in Vietnam

TIPRANKS
·
Aug 25

Solana price risks pullback as MACD turns bearish

cryptonews
·
Aug 24

Why Stockland (ASX:SGP) Is Up 13.2% After Strong FY26 Profit And Steady FY27 Guidance

Simply Wall St.
·
Aug 24

Stockland (ASX:SGP), Why Is It Back In The Spotlight?

Simply Wall St.
·
Aug 22

Press Release: Solana Company Announces Positions and Votes on First Solana Governance Proposals

Dow Jones
·
Aug 21

Stockland (ASX:SGP) Shares Eye Rerating After Top End FFO Print

Simply Wall St.
·
Aug 20

Stockland lifts profit and asset values as it reshapes property portfolio

TIPRANKS
·
Aug 19

Raymond James Initiates SpyGlass Pharma at Outperform, With $39 Price Target

MT Newswires Live
·
Aug 14

Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR)

TIPRANKS
·
Aug 14

Spyglass Pharma Posts Corporate Deck on Long-Acting Intraocular Drug Delivery for Glaucoma, Ocular Hypertension Patients

Reuters
·
Aug 13

SpyGlass Pharma: Buy Rating Reiterated as Late-Stage Glaucoma Pipeline Advances; $37 Price Target Maintained

TIPRANKS
·
Aug 08

SpyGlass Pharma Q2 FY26 Net Loss Widens to $19.9 Million; R&D Expenses Rise to $10.9 Million

Reuters
·
Aug 07

Spyglass Pharma Q2 EPS USD -0.59

THOMSON REUTERS
·
Aug 07